These findings carry significant clinical implications: accessible indicators like BMI and ALB enable preliminary screening and risk stratification in rural communities, where low values signal higher sarcopenia risk and help identify nutritionally compromised individuals; concurrently, serum biomarkers such as elevated GDF11 and reduced FGF19 show promise for precision diagnostics and risk prediction, guiding future blood-based early-screening tools. This evidence concerns the gene FGF19 and sarcopenia.